Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
Deficiency of the tumor suppressor merlin leads to the development of multiple tumors of the nervous system, such as schwannomas, meningiomas, and ependymomas. Due to the benign character of these tumors, classical chemotherapy is ineffective. Current therapies, surgery, and radiosurgery are local a...
Main Authors: | Sylwia Ammoun, Natalia Ristic, Cordula Matthies, David A. Hilton, C. Oliver Hanemann |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-01-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996109002691 |
Similar Items
-
Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
by: Keisuke Enomoto, et al.
Published: (2021-02-01) -
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target
by: Kayleigh Bassiri, et al.
Published: (2017-02-01) -
Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects
by: Yu Zhang, et al.
Published: (2021-09-01) -
Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia
by: Chelsea N. Zimmerman, et al.
Published: (2017-06-01) -
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
by: Xuejiao Liu, et al.
Published: (2019-05-01)